Abstract
Atrial fibrillation (AF) is one of the most prevalent arrythmias worldwide and associated with an increased risk of stroke and systemic thromboembolism. Stroke prevention with direct oral anticoagulation (DOAC) is recommended in patients with non-valvular AF (NVAF) at high risk of stroke. WATCHMANTM percutaneous left atrial appendage closure (LAAC) device is currently introduced as an alternative to DOAC for patients with NVAF ineligible for long-term administration of DOAC due to high risk of bleeding. This review article may contribute to recognize the paradigm shift in which stroke prevention should be carried out topically but not systemically, because left atrial appendage (LAA) is the main source of thrombus formation in AF patients. In addition, this review article introduces the current knowledge and future perspective of LAAC strategy and technology.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
